|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
intramuscular injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2006
|
|
gptkbp:brand
|
gptkb:Gardasil
gptkb:Cervarix
gptkb:Gardasil_9
|
|
gptkbp:broadcastOn
|
2 or 3 doses
|
|
gptkbp:canBe
|
immunocompromised individuals
|
|
gptkbp:contains
|
virus-like particles
|
|
gptkbp:contraindication
|
severe allergic reaction to vaccine component
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
GlaxoSmithKline
|
|
gptkbp:excludes
|
gptkb:virus
live virus
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
HPV Vaccine
|
|
gptkbp:includedIn
|
national immunization programs
|
|
gptkbp:notRecommendedFor
|
pregnant women
|
|
gptkbp:prevention
|
gptkb:cancer
anal cancer
human papillomavirus infection
genital warts
oropharyngeal cancer
|
|
gptkbp:protectedBy
|
gptkb:HPV_type_11
gptkb:HPV_type_16
gptkb:HPV_type_18
gptkb:HPV_type_31
gptkb:HPV_type_33
gptkb:HPV_type_45
gptkb:HPV_type_52
gptkb:HPV_type_58
gptkb:HPV_type_6
|
|
gptkbp:recommendation
|
gptkb:Centers_for_Disease_Control_and_Prevention
gptkb:World_Health_Organization
adolescents
preteens
adults up to age 45
|
|
gptkbp:reduces
|
gptkb:vaginal_cancer
throat cancer
penile cancer
vulvar cancer
cervical dysplasia
|
|
gptkbp:routeOfAdministration
|
intramuscular
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
pain at injection site
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:WHOStatus
|
essential medicines
|
|
gptkbp:bfsParent
|
gptkb:Immunization_Clinic
|
|
gptkbp:bfsLayer
|
5
|